|About Us||Research Areas||News|
|Our Team||Collaborations||Contact Us|
MagidAbou-Gharbia, Ph.D., FRSC, Associate Dean for Research, Professor of Medicinal Chemistry and Director of the Moulder Center for Drug Discovery Research (MCDDR), joined the faculty of Temple University's School of Pharmacy in 2008. His extensive experience in drug discovery and development includes 26 years with Wyeth Pharmaceuticals where he was senior Vice President and Head of Chemical and Screening Sciences. In this position, he was responsible for overseeing and directing the chemistry and screening research efforts of 500 scientists at four US research facilities and 150 chemists in Hyderabad, India. He and his research staff were responsible for drug discovery and development programs in Neuroscience, Inflammation, Women's Health/Bone, Oncology and Cardio-vascular/Metabolic Diseases therapeutic areas.
Pharma R&D Achievements: Over the years Dr. Abou-Gharbia's research efforts led to the discovery of five marketed drugs and many compounds currently under clinical evaluation including: the first-in-class antidepressant Effexor®; the anticancer agent Mylotarg®; an anticancer rapamycin derivative, Torisel™ (temsirolimus); an SNRI anti-depressant, Pristiq® (DVS-233); a broad spectrum antibiotic Tygacil®, and a non-steroidal, HRT Viviant™, (Bazedoxifene®).
Scientific Contributions include over 235 invited lectures, presentations and publications; inventor on 99 US patents and over 350 patents worldwide.
Awards and Honors: ACS Fellow (2010); Induction to ACS Medicinal Chemistry Hall of Fame (2008); ACS Heroes of Chemistry (2008); Alfred Burger Award in Medicinal Chemistry (2008); Science and Technology Medal from the R&D Council of New Jersey (2008); selected among the Top 10 Scientists in New Jersey by New Jersey Business Magazine (2008); American Institute of Chemists (AIC) Chemistry Pioneer Award (2007); Fellow of the Royal Society of Chemistry (FRSC 2006); Researcher of the Year (2006) from Health Care Institute of NJ (HINJ); Trailblazer Award (2006) from Science Spectrum; Induction into the New Jersey Inventors Hall of Fame (2004); The Procter Medal (2003); ACS Earle B. Barnes Award (2001); Philadelphia Organic Chemists Club (POCC) Award (2001); Egyptian Pharmaceutical Society Drug Discovery Award (2000); Named as one of the most Prolific Inventors of the Decade by US Patent & Trade Mark (1998); ACS-Philadelphia Section Award (1997); Wyeth-Ayerst Exceptional Achievement Award (1992); and others.
Scientific and Professional Activities include Member of the SAB of Galenea Pharmaceuticals (2009-present), Member of the Medicinal Chemistry SAB of Abbott Pharmaceutical (2010-present); Membership of the 2009 EPSRC International Review Panel responsible for evaluating the impact of chemical research in the UK; Fellow of the Royal Society of Chemistry (FRSC); member of the Advisory Board of Dow's Women Scientists; Board of Visitors of the College of Science and Technology (CST) , Temple University; C&E News Advisory Board; and on the editorial and scientific advisory boards of many journals.
Academic Appointments: Visiting Professor, Wolfson Centre for Age Related Diseases, School of Biomedical and Health Sciences, King's College London, Adjunct Professor at Northeastern University, Center of Drug Discovery (CDD), Chemistry and Biology department at Temple University, School of Pharmacy at Cairo University, University of Ferrara, IT and Scientific Advisor for the Chairman of the Board of Trustees of the Future University in Egypt.
Education: Dr. Abou-Gharibia received his BS in Pharmacy and Pharmaceutical Sciences (1971) and MS in Medicinal Chemistry (1974) from the School of Pharmacy, Cairo University. In 1979, he completed his Ph.D. at the University of Pennsylvania under the direction of Professor Madeleine Joullie, and then accepted a two year NIH Postdoctoral Fellowship with Temple University's Medical School and the Department of Chemistry.